| 0.466 -0.112 (-19.31%) | 10-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.74 |
1-year : | 2.51 |
| Resists | First : | 1.49 |
Second : | 2.15 |
| Pivot price | 0.72 |
|||
| Supports | First : | 0.43 |
Second : | 0.35 |
| MAs | MA(5) : | 0.56 |
MA(20) : | 0.87 |
| MA(100) : | 2.7 |
MA(250) : | 0 | |
| MACD | MACD : | -0.4  |
Signal : | -0.4 |
| %K %D | K(14,3) : | 4.1 |
D(3) : | 3 |
| RSI | RSI(14): 19.6 |
|||
| 52-week | High : | 94 | Low : | 0.43 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LABT ] has closed above bottom band by 2.1%. Bollinger Bands are 81.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for {EMPTY} bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.58 - 0.58 | 0.58 - 0.59 |
| Low: | 0.42 - 0.43 | 0.43 - 0.43 |
| Close: | 0.45 - 0.45 | 0.45 - 0.46 |
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Wed, 21 Oct 2026
Lakewood-Amedex presents antimicrobial data at IDWeek 2026 By Investing.com - Investing.com India
Thu, 15 Oct 2026
LABT Price Today: Lakewood-Amedex Biotherapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC
Thu, 08 Oct 2026
Lakewood-Amedex Announces Positive Preclinical Bisphosphocin® Com - The National Law Review
Fri, 02 Oct 2026
Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences - Kitsap Sun
Thu, 01 Oct 2026
Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 39.4 (%) |
| Held by Institutions | 6 (%) |
| Shares Short | 131 (K) |
| Shares Short P.Month | 61 (K) |
| EPS | -8.83 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -139.4 % |
| Return on Equity (ttm) | -402.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -0.06 |
| PEG Ratio | 0 |
| Price to Book value | 0.22 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.31 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|